See attachment(s) / Voir document(s) joint(s) / Zie bijlage / Ver documento(s) em anexo
Biophytis S A PRESENTS ITS DEVELOPMENT PROGRAMS IN OBESITY AND SARCOPENIA AT THE ICFSR CONFERENCE
Story so far
- Biophytis S A enters strategic agreement in Asia and secures $20 million for launch of Phase 3 trial in sarcopenia
- Biophytis S A and a Consortium of Investors including RONGHUI RENHE Life Technology Join Forces to Finance and Launch First-Ever Phase 3 Trial in Sarcopenia
- Biophytis S A Secures public funding in Brazil for Obesity Phase 2 Trial and Signs Agreements with Leading local Clinical Partners
Earlier from Biophytis
- Biophytis: LynxKite Alliance Expands to Turbocharge AI-driven drug discovery for next generation longevity therapeutics
- Biophytis S A ANNOUNCES COMPLETION OF OVER €2.0 MILLION CAPITAL INCREASE AND THE REPAYMENT OF ALL VARIABLE PRICE CONVERTIBLE DEBT
- Biophytis S A increases to €2 million the ceiling of its bond facility with Hexagon Capital Fund
- Biophytis S A conclut un accord stratégique en Asie et sécurise 20 M$ pour le lancement de sa Phase 3 dans la sarcopénie
- Biophytis S A enters strategic agreement in Asia and secures $20 million for launch of Phase 3 trial in sarcopenia
Later from Biophytis
- Information on annual financial statements
- Biophytis S A PROVIDES AN UPDATE AND SHARE STRATEGIC DRIVERS SUPPORTING ITS HONG KONG JOINT VENTURE
- Biophytis S A strengthens its financial position and extends its cash runway into Q1 2027
- Biophytis S A to evaluate BIO101’s potential to limit weight regain in its OBA clinical study in obesity
- Biophytis S A ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Follow Biophytis into a list and get an email when it puts out news.
Follow Biophytis